FDA releases safety announcement on possible heart failure risk for Mirapex


On Sept. 19, the US Food and Drug Administration released a safety announcement on Mirapex (pramipexole), used to treat Parkinson’s disease and restless legs syndrome, and the possible risk of heart failure. The announcement states, “Because of the study limitations, FDA is not able to determine whether Mirapex increases the risk of heart failure.” The FDA says health care professionals should continue to follow drug-label recommendations when prescribing Mirapex, and that it is continuing to work with the manufacturer to “clarify further the risk of heart failure with Mirapex.” Read more.


Please enter your comment!
Please enter your name here